Mutual of America Capital Management LLC Takes $4.62 Million Position in Elanco Animal Health Incorporated $ELAN

Mutual of America Capital Management LLC bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 229,442 shares of the company’s stock, valued at approximately $4,621,000.

Other large investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC lifted its stake in shares of Elanco Animal Health by 434.2% in the 2nd quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after acquiring an additional 102,686 shares during the last quarter. Norges Bank purchased a new position in Elanco Animal Health in the 2nd quarter worth approximately $12,502,000. Amalgamated Bank lifted its position in Elanco Animal Health by 793.7% in the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock valued at $4,563,000 after purchasing an additional 201,226 shares during the last quarter. Yousif Capital Management LLC boosted its stake in shares of Elanco Animal Health by 1,333.7% during the third quarter. Yousif Capital Management LLC now owns 168,133 shares of the company’s stock valued at $3,386,000 after purchasing an additional 156,406 shares during the period. Finally, Equitable Trust Co. grew its holdings in shares of Elanco Animal Health by 65.5% in the second quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock worth $3,543,000 after purchasing an additional 98,172 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons purchased 22,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 43,450 shares of company stock valued at $937,883. Company insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. UBS Group increased their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Barclays started coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.11.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.22 on Friday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $25.29. The stock has a market capitalization of $12.03 billion, a P/E ratio of 403.65, a P/E/G ratio of 3.35 and a beta of 1.87. The company’s 50-day moving average is $22.99 and its 200 day moving average is $20.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the firm posted $0.13 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.